Tu­mor-treat­ing elec­tric fields show ear­ly promise in NSCLC — boost­ing both Novo­cure and its Chi­nese biotech part­ner

More than a decade af­ter the FDA first ap­proved elec­tric fields as a treat­ment for glioblas­toma, Novo­cure said it’s seen a promis­ing sig­nal that they could al­so work against non-small cell lung can­cer.

Af­ter re­view­ing da­ta at an in­ter­im analy­sis, Novo­cure said, the in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee sug­gest­ed down­siz­ing and short­en­ing the Phase III tri­al — from 18-month fol­lowup on 534 pa­tients to 12-month fol­lowup on 276 pa­tients. Fol­low­ing the orig­i­nal tri­al pro­to­col is “like­ly un­nec­es­sary and pos­si­bly un­eth­i­cal,” the DMC told the com­pa­ny; giv­en what they have seen, a small­er tri­al with short­er fol­lowup should pro­vide suf­fi­cient sta­tis­ti­cal pow­er for both the pri­ma­ry end­point in over­all sur­vival and sec­ondary end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER